U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C16H20N2O2.C4H6O6
Molecular Weight 694.7712
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LADOSTIGIL TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1.CCN(C)C(=O)OC3=CC=C4CC[C@@H](NCC#C)C4=C3

InChI

InChIKey=PRLVBVAJMQZMJN-OGOSNNLPSA-N
InChI=1S/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1

HIDE SMILES / InChI

Molecular Formula C16H20N2O2
Molecular Weight 272.3422
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

LADOSTIGIL, a rasagiline derivative, is a reversible acetylcholinesterase and butyrylcholinesterase inhibitor with neuroprotective properties. It also acts as an irreversible brain monoamine oxidases inhibitor. It is under development for the treatment of neurodegenerative disorders like dementia and Alzheimer's disease.

Approval Year

PubMed

PubMed

TitleDatePubMed
Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.
2010-06
The role of rasagiline in the treatment of Parkinson's disease.
2010-05-25
The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.
2010
Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk.
2009-12-01
Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons.
2009-08-12
Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?
2009-04-02
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
2009-02
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
2009-01
The neurotrophic and neuroprotective effects of psychotropic agents.
2009
The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.
2008-09-25
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.
2008-08
The neuroprotective mechanism of action of the multimodal drug ladostigil.
2008-05-01
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.
2007-12
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.
2007-10
Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.
2007-08
Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats.
2007-03
The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection.
2007-02
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
2006-12
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
2006-12
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
2006-10
Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression.
2006
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
2005-10
Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats.
2005-08
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
2005-02
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
2004-12-02
Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
2004-03-25
Protein 4.1N is required for translocation of inositol 1,4,5-trisphosphate receptor type 1 to the basolateral membrane domain in polarized Madin-Darby canine kidney cells.
2003-02-07
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:05:59 GMT 2025
Edited
by admin
on Mon Mar 31 18:05:59 GMT 2025
Record UNII
2J1346C51H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LADOSTIGIL TARTRATE
USAN  
USAN  
Official Name English
TV-3326
Preferred Name English
CARBAMIC ACID, ETHYLMETHYL, (3R)-2,3-DIHYDRO-3-(2-PROPYNYLAMINO)-1H-INDEN-5-YL ESTER,(2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (2:1)
Common Name English
LADOSTIGIL TARTRATE [USAN]
Common Name English
(3R)-3-(Prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl ethylmethylcarbamate (2R,3R)-tartarate (2:1)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47792
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
NCI_THESAURUS C667
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
Code System Code Type Description
SMS_ID
300000044446
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
ChEMBL
CHEMBL255231
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
CAS
209394-46-7
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
NCI_THESAURUS
C76072
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
USAN
QQ-52
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
FDA UNII
2J1346C51H
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
PUBCHEM
11607225
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
EPA CompTox
DTXSID60175107
Created by admin on Mon Mar 31 18:05:59 GMT 2025 , Edited by admin on Mon Mar 31 18:05:59 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY